Guardant Health, Inc. (GH)
GH moved a median of -0.17% 30 minutes after news, and +0.22% by the close. How GH actually reacts to news — the realized, point-in-time move the market made, measured across 848 labeled events over the last three years with zero look-ahead.
GH’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 50% | 846 |
| 30-min | -0.17% | 47% | 846 |
| 60-min | -0.04% | 47% | 846 |
| to close | +0.22% | 51% | 842 |
| Middle 50% of GH reactions | -1.08% to +1.20% |
|---|---|
| Median reaction (30-min) | -0.17% |
| Measured reactions | 848 |
Half of all Guardant Health, Inc. news events land between -1.08% and +1.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GH reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 23 | -0.48% | 44% | -0.38% |
| Coverage initiations | 35 | +0.82% | 54% | +1.51% |
| Rating reiterations | 178 | +0.02% | 50% | -0.88% |
| Price-target raises | 56 | -0.11% | 41% | -0.41% |
| Price-target cuts | 11 | -0.85% | 36% | -0.92% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how GH ranks against every other measured name →
That’s how GH usually reacts — get an email when it moves on news →Email me when GH moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GH's baseline. Nothing else.
Recent GH events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests | Press release | Business Wire | +0.02% | +3.17% | |
| TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent | Press release | Business Wire | +0.03% | -4.39% | |
| Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer | Press release | Business Wire | +1.79% | +0.87% | |
| Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026 | Press release | Business Wire | +1.79% | +0.87% | |
| Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma | Press release | Business Wire | +0.39% | +3.40% | |
| Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening | Press release | Business Wire | +2.47% | +5.18% | |
| Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer | Press release | Business Wire | +0.09% | +0.14% | |
| Business Insider Names Guardant Health One of America's Most Innovative Businesses | Press release | Business Wire | +0.19% | -1.00% | |
| Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer | Press release | Business Wire | -0.33% | -3.09% | |
| Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening | Press release | Business Wire | +0.54% | +3.96% | |
| Guardant Health to Appeal Federal District Court Judgment | Press release | Business Wire | -0.13% | -0.82% | |
| TwinStrand Biosciences Announces Final Judgment in Patent Infringement Suit Against Guardant Health, Awarding TwinStrand and the University of Washington More Than $245.2 Million in Damages, Accrued Royalties and Interest | Press release | Business Wire | -0.70% | -0.88% | |
| Form 10-Q Guardant Health, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.10% | -0.89% | |
| Form 8-K Guardant Health, Inc. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | -0.89% | |
| Form S-3ASR Guardant Health, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +2.10% | -0.89% | |
| Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Press release | Business Wire | +2.10% | -0.89% | |
| Guardant Health to Participate in Upcoming Investor Conferences | Press release | Business Wire | +2.90% | +4.26% | |
| Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer | Press release | Business Wire | +0.17% | -1.23% | |
| Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 | Press release | Business Wire | -0.17% | -2.37% | |
| UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening | Press release | Business Wire | +1.06% | +1.36% | |
| Form 8-K Guardant Health, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | -0.73% | -1.78% | |
| Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS® | Press release | Business Wire | -0.55% | -1.10% | |
| Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting | Press release | Business Wire | -0.78% | +4.08% | |
| American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines | Press release | Business Wire | -1.86% | +3.39% | |
| FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint | Press release | Business Wire | +3.76% | +14.01% | |
| Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.34% | +3.28% | |
| Form 10-Q Guardant Health, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.87% | +2.87% | |
| Form 8-K Guardant Health, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.87% | +2.87% | |
| Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance | Press release | Business Wire | +1.87% | +2.87% | |
| Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations | Press release | Business Wire | +2.76% | +4.70% | |
| Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform | Press release | Business Wire | +0.23% | +3.54% | |
| Guardant Health to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.23% | +3.54% | |
| Form ARS Guardant Health, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.00% | +1.30% | |
| Form DEF 14A Guardant Health, Inc. For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | +2.00% | +1.30% | |
| Form DEFA14A Guardant Health, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +2.00% | +1.30% | |
| Form 8-K Guardant Health, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | -3.41% | |
| Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026 | Press release | Business Wire | -0.22% | +3.68% | |
| Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan | Press release | Business Wire | +0.18% | +1.40% | |
| Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data | Press release | PR Newswire | +0.98% | -1.72% | |
| Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 | Press release | Business Wire | -0.49% | -0.93% | |
| Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership | Press release | Business Wire | +1.01% | -0.03% | |
| New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare | Press release | Business Wire | +1.45% | +0.85% | |
| Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics | Press release | Business Wire | -0.21% | -1.34% | |
| Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America | Press release | Business Wire | -1.31% | -1.57% | |
| Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened | Press release | Business Wire | -1.43% | +3.56% | |
| Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.28% | +0.22% | |
| Form S-8 Guardant Health, Inc. | SEC filing · Form S-8 | SEC EDGAR | +3.11% | -4.54% | |
| Form 10-K Guardant Health, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.11% | -4.54% | |
| Form 8-K Guardant Health, Inc. For: Feb 19 | SEC filing · Form 8-K | SEC EDGAR | +3.11% | -4.54% | |
| Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook | Press release | Business Wire | +3.11% | -4.54% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GH section they belong to.
Where else GH is measured.
GH earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Lakeland Industries, Inc. (LAKE) | 849 | 0.00% | 46% |
| PROVIDENCE SERVICE (PRSC) | 849 | -0.01% | 47% |
| Capital Senior Living Corporation (CSU) | 847 | 0.00% | 50% |
| West Pharmaceutical Services, Inc. (WST) | 847 | -0.05% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Guardant Health, Inc.'s median reaction calculated?
Every labeled GH news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 848 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of GH's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GH's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.